AFT Pharmaceuticals

aftpharm.com

Back in 1997, husband and wife team Hartley and Marree Atkinson hit the road selling products direct to pharmacies. AFT Pharmaceuticals was formed with a big dream in mind. In Australasia, our product line now extends to over 130 prescription and non-prescription products. We have offices in Singapore, Kuala Lumpur, Sydney and Auckland (our HQ). We export or license our products to over 109 countries. Plus our Orphan Drugs Foundation provides access to lower cost pharmaceuticals for people with rare diseases within South East Asia and the Pacific.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

NOVARTIS COLLABORATES WITH DNDI FOR VISCERAL LEISHMANIASIS DRUG

Pharmaceutical Technology | February 25, 2020

news image

Swiss pharma giant Novartis and non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration and license agreement to jointly develop LXE408 for visceral leishmaniasis. LXE408 is an oral treatment for this parasitic disease, which is transmitted by the bite of a sand fly, and can be life-threatening if left untreated. The drug was initially discovered by Novartis with the financial backing of the Wellcome Trust. DNDi executive direct...

Read More

ACACIA PHARMA COMPLETES DRAWDOWN FROM €25 MILLION LOAN FACILITY FROM COSMO PHARMACEUTICALS TO SUPPORT US LAUNCHES OF BARHEMSYS® AND BYFAVO™

Acacia Pharma Group plc | October 12, 2020

news image

Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that it has drawn down the remaining €10 million available under its unsecured €25 million loan facility with Cosm...

Read More

CORONAVIRUS TRACKER: GILEAD'S REMDESIVIR; WHITE HOUSE'S VACCINE PROJECT; PFIZER, BIONTECH'S VACCINE PROGRESS; ASTRAZENECA'S PIPELINE

Fiercepharma | April 29, 2020

news image

As headlines multiplied and analysts began sussing out Gilead Sciences' first controlled trial readout on remdesivir, NIAID director Anthony Fauci hailed the drug as real progress against the virus. Meanwhile, word emerged that the Trump administration is working up a Manhattan Project style vaccine initiative, bringing biotech, pharma and federal agencies together to speed up the work—and let the U.S. government take on the financial risks. Plus, Pfizer and BioNTech said they've d...

Read More

Pharma Tech

FEDS REBUFF PFIZER'S PLEAS TO SPEED UP SUPPLIES OF COVID-19 VACCINE RAW MATERIALS

Pfizer | December 21, 2020

news image

Since the time Pfizer was fixed to partake in the U.S. government's Warp Speed exertion to get COVID-19 antibodies to showcase, the organization has made it very clear it didn't have to take any bureaucratic cash to build up the immunization. In any case, did that refusal of R&D subsidizing add to Pfizer's failure to produce more dosages of its mRNA antibody for the U.S. market? Pfizer could give more than the 100 million portions it guaranteed in it...

Read More
news image

NOVARTIS COLLABORATES WITH DNDI FOR VISCERAL LEISHMANIASIS DRUG

Pharmaceutical Technology | February 25, 2020

Swiss pharma giant Novartis and non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration and license agreement to jointly develop LXE408 for visceral leishmaniasis. LXE408 is an oral treatment for this parasitic disease, which is transmitted by the bite of a sand fly, and can be life-threatening if left untreated. The drug was initially discovered by Novartis with the financial backing of the Wellcome Trust. DNDi executive direct...

Read More
news image

ACACIA PHARMA COMPLETES DRAWDOWN FROM €25 MILLION LOAN FACILITY FROM COSMO PHARMACEUTICALS TO SUPPORT US LAUNCHES OF BARHEMSYS® AND BYFAVO™

Acacia Pharma Group plc | October 12, 2020

Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that it has drawn down the remaining €10 million available under its unsecured €25 million loan facility with Cosm...

Read More
news image

CORONAVIRUS TRACKER: GILEAD'S REMDESIVIR; WHITE HOUSE'S VACCINE PROJECT; PFIZER, BIONTECH'S VACCINE PROGRESS; ASTRAZENECA'S PIPELINE

Fiercepharma | April 29, 2020

As headlines multiplied and analysts began sussing out Gilead Sciences' first controlled trial readout on remdesivir, NIAID director Anthony Fauci hailed the drug as real progress against the virus. Meanwhile, word emerged that the Trump administration is working up a Manhattan Project style vaccine initiative, bringing biotech, pharma and federal agencies together to speed up the work—and let the U.S. government take on the financial risks. Plus, Pfizer and BioNTech said they've d...

Read More
news image

Pharma Tech

FEDS REBUFF PFIZER'S PLEAS TO SPEED UP SUPPLIES OF COVID-19 VACCINE RAW MATERIALS

Pfizer | December 21, 2020

Since the time Pfizer was fixed to partake in the U.S. government's Warp Speed exertion to get COVID-19 antibodies to showcase, the organization has made it very clear it didn't have to take any bureaucratic cash to build up the immunization. In any case, did that refusal of R&D subsidizing add to Pfizer's failure to produce more dosages of its mRNA antibody for the U.S. market? Pfizer could give more than the 100 million portions it guaranteed in it...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us